| Semaglutide | Novo Nordisk | ||
| 2 mg/1.5 mL and 4 mg/3 mL ; Solution, Subcutaneous |
More Than $1000 mn
|
||
|
More Than 5
|
More Than 5
|
||
|
More Than 5
|
None | ||
| None | None | ||
| OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus | |||
|
Yes
| |||
| Ozempic | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 | Patent 23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ****** | *** ********* | *** ********* | *** ********* | ****** ************ / ******** ********* ******* | *** ********* | *** ********* | *** ********* | *** ********* | ******* | *** ********* | ******* | ******* | *** ********* | *** ********* | *** ********* | ******* | *** ********* | *** ********* | ******* | *** ********* | *** ********* | *** ********* | *** ********* |
| ******* | *** ********* | *** ********* | *** ********* | ******* | *** ********* | *** ********* | *** ********* | *** ********* | ******* | *** ********* | ********* ** ****** ** ******* | ******* | *** ********* | *** ********* | ********* ** ****** ** ******* | ******* | *** ********* | ********* ** ****** ** ******* | ******* | *** ********* | *** ********* | ********* ** ****** ** ******* | ********* ** ****** ** ******* |
| ********* | *** ********* | ********* | ********* | ********* | ********* | ********* | *** ********* | ********* | ********* | ********* | ********* | ********* | *** ********* | ********* | ********* | ********* | ********* | ********* | ********* | ********* | ********* | ********* | ********* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| *** ****** | *** / ********* | **** **, **** | ******* | **** | ******* *** **** (***** ******) *** *** **** |
| ******* | *** / ********* | **** **, **** | ******* / ********* ** ****** ** ******* | **** | ******* *** **** (***** ******) *** *** **** |
| ********* | *** / ********* | **** **, **** | ******* | **** | ******* *** **** (***** ******) *** *** **** |
| Semaglutide | Novo Nordisk | ||
| 8 mg/ 3 mL; Solution, Subcutaneous |
More Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
None | ||
| None | None | ||
| OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus | |||
|
Yes
| |||
| Ozempic | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** | *** ********* | ********* ** ****** ** ***** | ****** ************ / ******** ********* ******* | ****** ************ / ******** ********* ******* | *** ********* | ********* ** ****** ** ***** | ********* ** ****** ** ***** | ********* ** ****** ** ***** | ********* ** ****** ** ***** | ********* ** ****** ** ***** | ********* ** ****** ** ***** | ********* ** ****** ** ***** | ********* ** ****** ** ***** | ********* ** ****** ** ***** | ********* ** ****** ** ***** | *** ********* | ********* ** ****** ** ***** | ********* ** ****** ** ***** | ********* ** ****** ** ***** | ********* ** ****** ** ***** | ********* ** ****** ** ***** | ********* ** ****** ** ***** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** | *** \ ********* | *** **, **** | ******* / ********* ** ****** ** ***** | **** | ******* *** **** *** *** **** |
| Semaglutide | Novo Nordisk | ||
| 2 mg/3 mL ; Injection |
More Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
None | ||
| None | None | ||
| OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as: an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. | |||
|
Yes
| |||
| Ozempic | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** | *** ********* | ******* | ******* | *** ********* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** | *** \ ********* | *** **, **** | ******* | **** | ******* *** **** *** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|